At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 23, 2026 at 16:14 ET
UroGen Pharma held its 2026 annual meeting of shareholders on June 22, 2026. Shareholders approved election of all 7 director nominees, amendments to the articles of association (tying shareholder proposals to Israeli Companies Law requirements), an amendment to the non-employee director and officer compensation policy regarding D&O insurance, and an amendment to the 2017 equity incentive plan increasing authorized shares by 1,000,000. All proposals received majority support. The filing is a routine post-meeting report with no financial data or business updates.
- Shareholders elected 7 directors to serve until the next annual meeting; all received substantial majority votes.
- Proposal 2 (Amended and Restated Articles) passed with 19,306,222 For vs 9,007,528 Against.
- Proposal 3 (Compensation Policy Amendment) passed with 26,089,418 For vs 2,182,017 Against.
- Proposal 4 (2017 Amended Plan) passed, increasing the share reserve by 1,000,000 shares to a total of 9,750,167 shares.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access